New Zealand markets open in 4 hours 24 minutes
  • NZX 50

    11,631.60
    -46.15 (-0.40%)
     
  • NZD/USD

    0.6345
    +0.0022 (+0.35%)
     
  • ALL ORDS

    7,487.70
    -40.10 (-0.53%)
     
  • OIL

    74.85
    -2.08 (-2.70%)
     
  • GOLD

    1,787.40
    +6.10 (+0.34%)
     

ADOCIA: Upcoming Investor Meetings

LYON, France, October 03, 2022--(BUSINESS WIRE)--Regulatory News:

Adocia (Euronext Paris: FR0011184241 - ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will attend the following investor events:

  • Investor Access (6 and 7 October 2022), in Paris

  • Biotech Agora (3 November 2022), in Paris

  • Kepler Cheuvreux - Life Sciences Day (21 November 2022), digital

As part of these professional meetings with the financial community through "one-to-one" or "one-to-few" formats, Adocia's management will review the latest clinical and scientific advances of its most advanced programs (BioChaperone Lispro, BioChaperone Combo, M1Pram) and detail the next expected catalysts relating in particular to the use of the disruptive technologies AdoShell and AdOral.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:

1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.

Adocia holds more than 25 patent families.

Based in Lyon, the company has approximately 115 employees. Adocia is listed on the EuronextTM Paris market (Euronext: ADOC; ISIN: FR0011184241).

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com, in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005661/en/

Contacts

Adocia
Gérard Soula
CEO
contactinvestisseurs@adocia.com
Tel : +33 (0)4 72 610 610
www.adocia.com

Ulysse Communication
Adocia Press and Investors Relations
Pierre-Louis Germain
Margaux Puech Pays d’Alissac
Bruno Arabian
adocia@ulysse-communication.com
+ 33 (0)6 64 79 97 51